Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 9/20 | 0.52 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491900 | 0.88 | PPARA (0.62) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL4818304 | 0.88 | PPARA (0.62) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL8239145 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL17492215 | 0.87 | PPARA (0.57) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL345468 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL17491991 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL4816376 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL17492218 | 0.87 | PPARA (0.57) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL16384487 | 0.85 | PPARA (0.58) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL17373574 | 0.85 | PPARA (0.53) | ITGB3ITGA2BPPARAPPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842806-B2 | Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-20090048277-A1 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-02-19 | — | — | US | disclosed |
| EP-1979352-A2 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007080324-A2 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | SANOFIS-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048277-A1 | PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF | DPYD, TYMP, PDXK | ITGB3 2839/4885ITGA2B 3711/4885PPARA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.